PDS Biotech has been granted Fast Track designation for PDS0101 in combination with KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer
https://finance.yahoo.com/news/pds-biotechnology-granted-fda-fast-120000127.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.